Literature DB >> 22706011

The design and evaluation of HIV-1 vaccines.

Kevin O Saunders1, Rebecca S Rudicell, Gary J Nabel.   

Abstract

There is renewed optimism that the goal of developing a highly effective AIDS vaccine is attainable. The HIV-1 vaccine field has seen its first trial of a vaccine candidate that prevents infection. Although modest in efficacy, this finding, along with the recent discovery that the human immune system can produce broadly neutralizing antibodies capable of inhibiting greater than 90% of circulating viruses, provides a guide for the rational design of vaccines and protection by passive immunization. Together, these findings will help shape the next generation of HIV vaccines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706011      PMCID: PMC7480282          DOI: 10.1097/QAD.0b013e32835474d2

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  106 in total

1.  Timing the ancestor of the HIV-1 pandemic strains.

Authors:  B Korber; M Muldoon; J Theiler; F Gao; R Gupta; A Lapedes; B H Hahn; S Wolinsky; T Bhattacharya
Journal:  Science       Date:  2000-06-09       Impact factor: 47.728

2.  Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Authors:  John R Mascola; Anna Sambor; Kristin Beaudry; Sampa Santra; Brent Welcher; Mark K Louder; Thomas C Vancott; Yue Huang; Bimal K Chakrabarti; Wing-Pui Kong; Zhi-Yong Yang; Ling Xu; David C Montefiori; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 3.  Novel adenovirus vector-based vaccines for HIV-1.

Authors:  Dan H Barouch
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

4.  Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors:  J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Authors:  Amandeep K Dhillon; Helen Donners; Ralph Pantophlet; Welkin E Johnson; Julie M Decker; George M Shaw; Fang-Hua Lee; Douglas D Richman; Robert W Doms; Guido Vanham; Dennis R Burton
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

6.  Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency.

Authors:  C Tkaczyk; L Hua; R Varkey; Y Shi; L Dettinger; R Woods; A Barnes; R S MacGill; S Wilson; P Chowdhury; C K Stover; B R Sellman
Journal:  Clin Vaccine Immunol       Date:  2012-01-11

Review 7.  Rational modifications of HIV-1 envelope glycoproteins for immunogen design.

Authors:  S Phogat; R Wyatt
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

8.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.

Authors:  Barney S Graham; Richard A Koup; Mario Roederer; Robert T Bailer; Mary E Enama; Zoe Moodie; Julie E Martin; Margaret M McCluskey; Bimal K Chakrabarti; Laurie Lamoreaux; Charla A Andrews; Phillip L Gomez; John R Mascola; Gary J Nabel
Journal:  J Infect Dis       Date:  2006-11-08       Impact factor: 5.226

9.  HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.

Authors:  Peter B Gilbert; Marta L Ackers; Phillip W Berman; Donald P Francis; Vladimir Popovic; Dale J Hu; William L Heyward; Faruk Sinangil; Bryan E Shepherd; Marc Gurwith
Journal:  J Infect Dis       Date:  2005-08-12       Impact factor: 5.226

10.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys.

Authors:  Philip R Johnson; Bruce C Schnepp; Jianchao Zhang; Mary J Connell; Sean M Greene; Eloisa Yuste; Ronald C Desrosiers; K Reed Clark
Journal:  Nat Med       Date:  2009-05-17       Impact factor: 53.440

View more
  19 in total

Review 1.  HIV-1 vaccines: challenges and new perspectives.

Authors:  Jean-Louis Excler; Merlin L Robb; Jerome H Kim
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

2.  Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.

Authors:  Samantha Townsley; Yun Li; Yury Kozyrev; Brad Cleveland; Shiu-Lok Hu
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

3.  Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.

Authors:  Ivelin S Georgiev; Rebecca S Rudicell; Kevin O Saunders; Wei Shi; Tatsiana Kirys; Krisha McKee; Sijy O'Dell; Gwo-Yu Chuang; Zhi-Yong Yang; Gilad Ofek; Mark Connors; John R Mascola; Gary J Nabel; Peter D Kwong
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

4.  Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects.

Authors:  Missa P Sanou; Shannon R Roff; Antony Mennella; John W Sleasman; Mobeen H Rathore; Janet K Yamamoto; Jay A Levy
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

5.  An infectious molecular clone in early infection with HIV-1 subtype CRF01_AE strains: construction and biological properties.

Authors:  Hong-Wei Wang; Bin Zhu; Li-Juan Hou; Guang-Jian Lu; Lu-Yang Jiao; Bao-Sheng Shen
Journal:  Mol Biol Rep       Date:  2014-11-06       Impact factor: 2.316

Review 6.  Immunopathogenesis of simian immunodeficiency virus infection in nonhuman primates.

Authors:  Joern E Schmitz; Birgit Korioth-Schmitz
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

7.  Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Authors:  Samantha Townsley; Zeinab Mohamed; Wenjin Guo; Jennifer McKenna; Brad Cleveland; Celia LaBranche; David Beaumont; Xiaoying Shen; Nicole L Yates; Abraham Pinter; Georgia D Tomaras; Guido Ferrari; David C Montefiori; Shiu-Lok Hu
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 8.  New clinical trial designs for HIV vaccine evaluation.

Authors:  Zoe Moodie; Holly Janes; Yunda Huang
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

Review 9.  Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS.

Authors:  Janet Chung; David L DiGiusto; John J Rossi
Journal:  Expert Opin Biol Ther       Date:  2013-03       Impact factor: 4.388

10.  Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition.

Authors:  Tamika L Payne; Jeff Blackinton; Alyse Frisbee; Joy Pickeral; Sheetal Sawant; Nathan A Vandergrift; Stephanie A Freel; Guido Ferrari; Jack D Keene; Georgia D Tomaras
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.